Glyxambi
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 2356
  • Home
  • Print this page
  • Email this page
SYMPOSIUM
Year : 2007  |  Volume : 55  |  Issue : 6  |  Page : 417-420

Bevacizumab: Off-label use in ophthalmology


University Eye Hospital at the Centre of Ophthalmology, Eberhard-Karls University of Tuebingen, Germany

Correspondence Address:
Salvatore Grisanti
University Eye Hospital, Centre of Ophthalmology, Eberhard-Karls University of Tuebingen Schleichstrasse 12-15 72076 Tuebingen
Germany
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0301-4738.36474

Rights and Permissions

Bevacizumab is a full-length, humanized monoclonal antibody directed against all the biologically active isoforms of vascular endothelial growth factor (VEGF-A). The antibody was initially designed and studied as an anti-angiogenic strategy to treat a variety of solid tumors. After approval by the US Food and Drug Administration, bevacizumab gained access into ophthalmology to treat various types of neovascular diseases. Since the first report in 2005 more than 100 publications share the experience with bevacizumab in ophthalmology. Two authors independently assessed the research results from Pubmed to April 2007. The reference list is a selection of key publications related to the issue. Currently, there is no well-designed randomized controlled trial yet to establish the efficacy and safety of intraocular bevacizumab for any ocular disease in spite of its assumed characteristics representing the most cost-effective VEGF inhibitor.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed8769    
    Printed156    
    Emailed6    
    PDF Downloaded1147    
    Comments [Add]    
    Cited by others 5    

Recommend this journal